The use of chemical design tools to transform proteomics data into drug candidates.
The Human Genome Project has fueled the massive information-driven growth of genomics and proteomics and promises to deliver new insights into biology and medicine. Since proteins represent the majority of drug targets, these molecules are the focus of activity in pharmaceutical and biotechnology organizations. In this article, we describe the processes by which computational drug design may be used to exploit protein structural information to create virtual small molecules that may become novel medicines. Experimental protein structure determination, site exploration, and virtual screening provide a foundation for small molecule generation in silico, thus creating the bridge between proteomics and drug discovery.
Dean
Philip M
PM
De Novo Pharmaceuticals Ltd, Cambridge, UK.
Zanders
Edward D
ED
D020650:Combinatorial Chemistry Techniques / Q000379:methods*; D015195:Drug Design; D006801:Humans; D020543:Proteome / Q000032:analysis* / Q000737:chemistry*
D020543:Proteome